NCT02250027View on ClinicalTrials.gov

A Multicenter, Randomized, Double-blind, Parallel Group Study to Determine the Optimal Dose of HL301 After 7 Days Oral Administration in Acute Bronchitis or Acute Exacerbations of Chronic Bronchitis Patients (HL301: Mixed Extract of Rehmannia Glutinosa, Schisandra and so on)

PHASE2CompletedINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Acute BronchitisAcute Exacerbations of Chronic Bronchitis
Interventions
DRUG

HL301 300mg capsule

2 capsules at once, 3 times a day, for 7 days

DRUG

Placebo

2 capsules at once, 3 times a day, for 7 days

Trial Locations (1)

130-872

Kyung Hee University Hospital, Seoul

All Listed Sponsors
lead

Hanlim Pharm. Co., Ltd.

INDUSTRY

NCT02250027 - A Multicenter, Randomized, Double-blind, Parallel Group Study to Determine the Optimal Dose of HL301 After 7 Days Oral Administration in Acute Bronchitis or Acute Exacerbations of Chronic Bronchitis Patients (HL301: Mixed Extract of Rehmannia Glutinosa, Schisandra and so on) | Biotech Hunter | Biotech Hunter